| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/29/2006 | US20060140962 Combination treatment of pancreatic cancer |
| 06/29/2006 | US20060140961 Compositions and methods for the diagnosis and treatment of tumor |
| 06/29/2006 | US20060140960 identifying patients whose cancers are likely to be responsive to IGF1R (Insulin-like Growth Factor 1 Receptor) inhibitory anti-cancer therapy; treating a non-small cell lung tumor, an ovarian tumor, a neuroblastoma tumor or an osteosarcoma tumor in a mammalian |
| 06/29/2006 | US20060140959 Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof |
| 06/29/2006 | US20060140958 Tumor antigen (TAG); labeled nucleotide sequence; gives rise to antigenic peptides which bind to major histocompatibility complex and recognized by cytotoxic lymphocytes; diagnosis and treatment of cancer |
| 06/29/2006 | US20060140957 Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
| 06/29/2006 | US20060140956 Method and compounds for inhibiting hec1 ativity for the treatment of proliferative diseases |
| 06/29/2006 | US20060140955 Specific isotype antibodies of secretion-excretion anti-antigens of leishmania sp of promastigote or amastigote forms used as protection, resistance and curing markers of mammals to leishmaniases and to intracellular pathogenic micro-organism infections, and as immunotherapeutic effectors |
| 06/29/2006 | US20060140954 Novel human protein kinases and protein kinase-like enzymes |
| 06/29/2006 | US20060140953 Systems and methods for treating human inflammatory and proliferative diseases and wounds, with UCP and/or FAS antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor |
| 06/29/2006 | US20060140952 Tumour necrosis factor binding ligands |
| 06/29/2006 | US20060140951 Tumour necrosis factor binding ligands |
| 06/29/2006 | US20060140950 Using interleukin-23 modulators to treat and prevent nervous system, gastrointestinal and autoimmune disorders |
| 06/29/2006 | US20060140949 IgG4 constant region; Fab' fragment; antibody or antigen binding fragment inhibits binding of A2 or cA2 to human TNF- alpha , and binds to a neutralizing epitope of human TNF- alpha; immunoassays and immunotherapeutic agent |
| 06/29/2006 | US20060140948 Sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's) |
| 06/29/2006 | US20060140947 Administering decitabine and tyrosine kinase inhibitor such as epidermal growth factor receptor family (EGFR); cancer therapy; chronic myelogenous leukemia |
| 06/29/2006 | US20060140946 Anti-TNF chimeric antibody fragments |
| 06/29/2006 | US20060140945 Nephropathy-associated gene |
| 06/29/2006 | US20060140944 Novel polypeptides involved in immune response |
| 06/29/2006 | US20060140943 Immunotherapy using modulators of notch signalling |
| 06/29/2006 | US20060140942 Human G-protein coupled receptor (HETGQ23) |
| 06/29/2006 | US20060140941 Growth differentiation factor-3 |
| 06/29/2006 | US20060140940 Anti-hgf-r antibodies and their use |
| 06/29/2006 | US20060140939 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 06/29/2006 | US20060140938 peroxisome proliferator activated receptor |
| 06/29/2006 | US20060140937 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 06/29/2006 | US20060140936 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| 06/29/2006 | US20060140935 Platlet glycoprotein Ib alpha fusion polypeptides and methods of use thereof |
| 06/29/2006 | US20060140934 immunoglobulin domain peptides having myostatin, erythropoietin or thrombopoietin peptides as an internal sequence, preferably in a loop region of the domain; antibodies |
| 06/29/2006 | US20060140933 Compositions and methods for treating rage-associated disorders |
| 06/29/2006 | US20060140932 Human il-1 beta antagonists |
| 06/29/2006 | US20060140931 Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| 06/29/2006 | US20060140930 Promotion of central nervous system remyelination using monoclonal autoantibodies |
| 06/29/2006 | US20060140928 Use of heparinases to decrease inflammatory response |
| 06/29/2006 | US20060140922 Modified by introduction of nucleic acid molecule comprising a nucleic acid sequence encoding granulocyte macrophage-colony stimulating factor (GM-CSF) operably linked to a promoter; contains cancer antigen; immunotherapy |
| 06/29/2006 | US20060140920 Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain |
| 06/29/2006 | US20060140919 Methods for selectively stimulating proliferation of T cells |
| 06/29/2006 | US20060140912 Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients |
| 06/29/2006 | US20060140907 Central airway administration for systemic delivery of therapeutics |
| 06/29/2006 | US20060140903 Diagnoses and treatment of disorders using an alternative glucose pathway |
| 06/29/2006 | US20060140874 Stable aerosol formulations of peptides and protein with non-cfc propellants |
| 06/29/2006 | CA2799802A1 Antibodies directed to angiopoietin-2 and uses thereof |
| 06/29/2006 | CA2594524A1 Saccharide conjugate vaccines |
| 06/29/2006 | CA2593746A1 Compositions of influenza viral proteins and methods of use thereof |
| 06/29/2006 | CA2592439A1 Rescue of influenza virus |
| 06/29/2006 | CA2592249A1 Binding proteins specific for human matriptase |
| 06/29/2006 | CA2592201A1 Neuromedin s and the use thereof |
| 06/29/2006 | CA2592156A1 Vaccines against neisseria meningitidis |
| 06/29/2006 | CA2592005A1 Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone |
| 06/29/2006 | CA2591813A1 Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| 06/29/2006 | CA2591786A1 Prevention of thrombus formation and/or stabilization |
| 06/29/2006 | CA2591768A1 Cancer specific antibody and cell surface proteins |
| 06/29/2006 | CA2591665A1 Binding molecules capable of neutralizing west nile virus and uses thereof |
| 06/29/2006 | CA2591510A1 Group b streptococcus |
| 06/29/2006 | CA2591304A1 Compositions and methods relating to anti-igf-1 receptor antibodies |
| 06/29/2006 | CA2590936A1 Combination therapy for b cell disorders |
| 06/29/2006 | CA2590471A1 Combination treatment for multiple sclerosis |
| 06/29/2006 | CA2572389A1 Vaccine compositions for treating coronavirus infection |
| 06/28/2006 | EP1674576A1 Recombinant allergen with reduced enzymatic activity |
| 06/28/2006 | EP1674575A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 06/28/2006 | EP1674574A1 Methods for Regulating Hematopoiesis using CpG-Oligonucleotides |
| 06/28/2006 | EP1674564A1 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor |
| 06/28/2006 | EP1674111A1 Anti-glypican 3 antibody |
| 06/28/2006 | EP1674110A1 Inhibition of bradykinin release |
| 06/28/2006 | EP1674108A2 Osteoporosis treatment |
| 06/28/2006 | EP1673633A1 Method and device for detecting feline immunodeficiency virus |
| 06/28/2006 | EP1673475A2 Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt |
| 06/28/2006 | EP1673461A1 Chimeric carrier molecules for the production of mucosal vaccines |
| 06/28/2006 | EP1673458A1 Poxvirus vector encoding retrovirus (eg hiv) and cytokine |
| 06/28/2006 | EP1673449A2 Immunogenic composition and method of developing a vaccine based on fusion protein |
| 06/28/2006 | EP1673448A2 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv |
| 06/28/2006 | EP1673447A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein |
| 06/28/2006 | EP1673395A1 Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| 06/28/2006 | EP1673394A2 Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent |
| 06/28/2006 | EP1673393A2 Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity |
| 06/28/2006 | EP1673106A1 Optimized expression of hpv 45 l1 in yeast |
| 06/28/2006 | EP1597370B1 Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
| 06/28/2006 | EP1392330B1 Use of lps for treating intestinal inflammation processes |
| 06/28/2006 | EP1353689B9 Immunizing compositions and methods of use |
| 06/28/2006 | EP1255561B1 Proteosome influenza vaccine |
| 06/28/2006 | EP1218031B1 Pharmaceutical composition comprising an antigen |
| 06/28/2006 | EP1136077B1 Preparations containing virus-like particles as immunopotentiators administered through the mucosa |
| 06/28/2006 | EP1060251B1 Phosphodiesterase 10 |
| 06/28/2006 | EP0990041B1 Regulation of transcription in mammalian cells and viral replication by a tetracyclin repressor |
| 06/28/2006 | EP0897426B1 Matrix metalloprotease |
| 06/28/2006 | EP0895543B1 Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens |
| 06/28/2006 | EP0882799B1 Anti-human vegf receptor flt-1 monoclonal antibody |
| 06/28/2006 | EP0787138B1 Radioactive phosphorous labeling of proteins for targeted radiotherapy |
| 06/28/2006 | EP0757722B1 HERPES VIRUS TRANSFORMED TO EXPRESS gD IN VITRO |
| 06/28/2006 | EP0712414B1 Recombinant vector containing a lipoprotein gene sequence for expressing nucleotide sequences |
| 06/28/2006 | CN1795208A Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| 06/28/2006 | CN1795207A Anti-amyloid antibodies, compositions, methods and uses |
| 06/28/2006 | CN1795205A Spex compositions and methods of use |
| 06/28/2006 | CN1795027A Composition comprising lactobacilli or bifidobacteria and use thereof |
| 06/28/2006 | CN1795010A Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
| 06/28/2006 | CN1795009A Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 06/28/2006 | CN1793367A Tubercle bacillus recombined protein and expressing purefying method and application thereof |
| 06/28/2006 | CN1793179A Optimizing fusion protein containing VEGF recerver segment and medical application thereof |
| 06/28/2006 | CN1261564C Artificial recombined influenza virus and its application |
| 06/28/2006 | CN1261454C Preparation of anti-caries bacteria IgY, and anti-caries composition |